Northern Arizona Healthcare Partners with InsightRX on the First Commercial Precision Dosing Model for Heparin

~ Flagstaff, Arizona - In a joint effort to improve patient outcomes, InsightRX and Northern Arizona Healthcare (NAH) have announced the availability of InsightRX's precision dosing software for heparin therapy at Flagstaff Medical Center. This deployment is expected to significantly decrease the time it takes to therapeutically dose hospitalized patients with unfractionated heparin, a common treatment for blood clots.

NAH, a multi-site not-for-profit health system, has long recognized the importance of precision dosing in advancing medical practice. They have chosen InsightRX's continuous learning platform as the solution for standardizing high-quality care practices.

"We are excited to integrate InsightRX into our daily Cerner workflows and individualize heparin therapy with the most advanced methods of patient safety monitoring," said Dr. Scott Waldrop, system director of pharmacy at NAH.

InsightRX's integrated heparin dosing platform seamlessly imports patient data from NAH's electronic health records and creates a real-time graph of a patient's coagulation status using their current blood draw. This allows clinicians to better identify patients with abnormal bleeding disorders or those at high risk for severe blood clots. Additionally, clinicians can simulate the impact of a recommended heparin dose before verifying the prescription.

More on The Arizonar
According to Dr. Jon Faldasz, senior director of product and customer experience at InsightRX, determining the right dose of anticoagulants has always been challenging due to individual variations in how patients metabolize medication. "Despite advances in therapeutic heparin dosing and monitoring, each patient eliminates heparin at their own rate based on variables such as size, blood composition, and underlying disease state," said Faldasz.

NAH has been utilizing InsightRX's flagship infectious disease modules for over three years to review approximately 5,600 treatment courses of vancomycin. With this new deployment, they will now have access to a comprehensive anticoagulation stewardship program, further enhancing their patient care.

This announcement follows successful deployments of InsightRX's Nova and Apollo platforms at approximately 800 hospitals in the U.S., impacting over one million patients. In the first quarter of this year, CIBC Innovation Banking provided growth financing to InsightRX, allowing them to enhance the development of new therapies and integrate artificial intelligence (AI) into healthcare.

More on The Arizonar
NAH has also recently announced plans to expand their healthcare system with a new hospital and renovations to existing facilities. The Central Flagstaff Clinic is set to open in 2024 with expanded cardiology services, primary care offices, and an urgent care clinic. They will also be remodeling and expanding an outpatient surgery center at the former Summit Center property, expected to reopen in mid-2026.

With this partnership between InsightRX and NAH, patients at Flagstaff Medical Center can expect improved precision dosing for heparin therapy and better overall outcomes. This deployment marks another step towards advancing medical practice through technology and innovation.
Filed Under: Business

Show All News | Report Violation


Latest on The Arizonar